首页MOLN • NASDAQ
add
Molecular Partners AG
相关资讯
财务信息
损益表
收入
净收入
| (CHF) | 2025年12月info | 年同比变化 |
|---|---|---|
收入 | — | — |
经营支出 | 4362.00万 | 716.09% |
净收入 | — | — |
净利润率 | — | — |
每股收益 | -0.36 | -20.00% |
息税折旧摊销前利润 | — | — |
有效税率 | -0.03% | — |
资产负债表
总资产
负债总额
| (CHF) | 2025年12月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 9305.80万 | -37.73% |
总资产 | 1.02亿 | -35.59% |
负债总额 | 2177.30万 | 28.90% |
权益总额 | — | — |
发行在外的股份 | 3778.51万 | — |
市净率 | 2.21 | — |
资产回报率 | -29.56% | — |
资本回报率 | -34.98% | — |
现金流
现金净变动
| (CHF) | 2025年12月info | 年同比变化 |
|---|---|---|
净收入 | — | — |
来自运营的现金 | -1115.10万 | 15.49% |
投资现金 | 1195.20万 | 365.95% |
融资现金 | -30.00万 | -101.96% |
现金净变动 | 29.40万 | 115.65% |
自由现金流 | -1501.71万 | -136.94% |
简介
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
成立时间
2004
员工数量
153
